Evidence map›Paper›PMID 39719802›Full record

ArticleStem cell research2025

Generation of induced pluripotent stem cell lines TRNDi037-A and TRNDi038-A from two patients with Alagille syndrome carrying heterozygous JAG1 mutations.

Elena F Evans, Guibin Chen, Ivan Pavlinov, Xiuli Huang, Kaari Linask, Chengyu Liu, Alexander Rodriguez Lopez, Melissa A Gilbert, Nancy B Spinner, Steven Rodemse and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elena F EvansNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Guibin ChenNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Ivan PavlinovNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Xiuli HuangNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Kaari LinaskiPSC Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Chengyu LiuTransgenic Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Alexander Rodriguez LopezNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Melissa A GilbertDivision of Genomic Diagnostics, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nancy B SpinnerDivision of Genomic Diagnostics, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Steven RodemseTravere Therapeutics, 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA.
Karsten BaumgärteleTravere Therapeutics, 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA.
Catherine Z ChenNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.
Jizhong ZouiPSC Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Wei ZhengNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA. Electronic address: wzheng@mail.nih.gov.

Funding

Drug Repurposing Screening for Rare and Neglected DiseasesZIATR000018 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI ZHENG, WEI · 2015 to 2025
$24.6M
Intramural NIH HHS ZIA TR000018
6 · The paper itself

Abstract

Human induced pluripotent stem cell (iPSC) lines TRNDi037-A and TRNDi038-A were generated from the lymphoblastoid cell lines (LCL) of two patients with different heterozygous JAG1 variants resulting in Alagille syndrome (ALGS). ALGS is a rare genetic disease of haploinsufficiency that affects the formation of the bile duct, in addition to other symptoms. These ALGS iPSC lines can be used to model ALGS and aid in the identification of therapeutics to treat patients with ALGS.

Indexed as

Alagille SyndromeHeterozygoteInduced Pluripotent Stem CellsJagged-1 ProteinMutationCell LineFemaleHumansMaleJAG1 protein, humanJagged-1 Protein

Identifiers

PMID39719802
PMCPMC11787771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.